Epithelial cell death markers in bronchoalveolar lavage correlate with chronic lung allograft dysfunction subtypes and survival in lung transplant recipients-a single-center retrospective cohort study
Evidence level: retrospective human biomarker study; abstract-only
A small retrospective study finding higher bronchoalveolar lavage M65 (a marker of epithelial cell death) in RAS than in BOS or CLAD-free controls.
As of . Primary source: Publisher record via DOI.
Summary
The study measured M30 and M65, cytokeratin-18 fragments released during epithelial cell apoptosis and total cell death, in bronchoalveolar lavage (BAL) fluid. Samples came from 26 patients with established CLAD (10 with RAS and 16 with BOS) and 19 long-term CLAD-free controls, with infection and acute rejection excluded. The abstract reports that M65 was significantly higher in RAS than in BOS and controls and correlated with worse survival after CLAD onset. The authors conclude that lung epithelial cell death is enhanced in RAS and that BAL M65 may help differentiate CLAD subtypes and serve as a prognostic marker. The cohort is small and single-centre, and the centre is not named in the abstract.
Details
- doi
- 10.1111/tri.13444
- pmid
- 31002407
- authors
- Levy L, Tigert A, Huszti E, Saito T, Mitsakakis N, Moshkelgosha S, Joe B, Boonstra KM, Tikkanen JM, Keshavjee S, Juvet SC, Martinu T
- journal
- Transplant International
- year
- 2019
- volume
- 32
- issue
- 9
- pages
- 965-973
Sources and links
- Publisher record via DOI (primary)
- PubMed 31002407
Related
Links from this record
- compares: Restrictive allograft syndrome (RAS)
- compares: Bronchiolitis obliterans syndrome (BOS)
- reports: Epithelial injury markers
- supports: Airway epithelial dysfunction
- coauthor: Tereza Martinu
- coauthor: Stephen Juvet
Linked from (derived)
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- author affiliations
- centre or centres not stated in the abstract
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.